公开(公告)号：US20230414575A1

公开(公告)日：2023-12-28

申请号：US18036713

申请日：2021-11-12

Applicant: Akttyva Therapeutics, Inc.

Inventor： Katya Tsaioun ,  Usamah Kayyali ,  Bruno Villoutreix

IPC: A61K31/42 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5415 ,  A61K31/4468 ,  A61P37/04

CPC classification number: A61K31/42 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5415 ,  A61K31/4468 ,  A61P37/04

Abstract: Provided herein are MK2 activators, and compositions comprising an MK2 activator, for the treatment of a vascular disorder or an endothelial barrier disorder in a patient in need thereof, whereby the MK2 activator has a molecular weight below 1000 Da and binds to a binding pocket located on the C-lobe domain and C-terminal Regulatory Domain of MK2. Also provided are methods of treating a vascular disorder or an endothelial barrier disorder in a patient by administering to the patient an MK2 activator.

公开(公告)号：US11826370B2

公开(公告)日：2023-11-28

申请号：US18062729

申请日：2022-12-07

Applicant: AXSOME THERAPEUTICS, INC.

Inventor： Herriot Tabuteau

IPC: A61K31/5415 ,  A61K31/4196 ,  A61P25/06

CPC classification number: A61K31/5415 ,  A61K31/4196 ,  A61P25/06

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

公开(公告)号：US11826369B2

公开(公告)日：2023-11-28

申请号：US16834061

申请日：2020-03-30

Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

Inventor： Arrigo DeBenedetti ,  Siddhant Bhoir ,  Vibha Singh ,  Javeena Hussain ,  Rupesh Chikhale ,  Richard Bryce ,  Sivapriya Kirubakaran

IPC: A61K31/5415 ,  A61K31/167 ,  A61P35/00

CPC classification number: A61K31/5415 ,  A61K31/167 ,  A61P35/00

Abstract: A method of treating prostate cancer in a patient comprising administering to the patient a pharmaceutical composition including a first therapeutic including a TLK1B inhibitor, or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, and a second therapeutic including an antiandrogen or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof.

公开(公告)号：US20230372355A1

公开(公告)日：2023-11-23

申请号：US18323040

申请日：2023-05-24

Applicant: AXSOME THERAPEUTICS, INC.

Inventor： Herriot Tabuteau

IPC: A61K31/5415 ,  A61K31/4196 ,  A61K47/61 ,  A61P25/06

CPC classification number: A61K31/5415 ,  A61K31/4196 ,  A61K47/61 ,  A61P25/06

Abstract: Disclosed herein is a method of treating migraine in patients with a history of inadequate response to prior migraine treatments comprising: selecting a patient who, for at least the past month: 1) has had 2 to 8 migraines per month, and 2a) according to the patient, is never or rarely comfortable enough with the patient's migraine medication to be able to plan daily activities, 2b) according to the patient, after taking migraine medication, the patient never or rarely feels in control of the patient's migraines enough so that the patient feels there will be no disruption in the patient's daily activities, 2c) has an mTOQ-4 score of 0, and/or 2d) has a history of depression; and administering a combination of 20 mg of meloxicam and 10 mg of rizatriptan to the patient during a migraine attack.

公开(公告)号：US20230321245A1

公开(公告)日：2023-10-12

申请号：US18012795

申请日：2021-07-02

Applicant: MEDINCELL S.A.

Inventor： Juliette Serindoux ,  Adolfo Lopez Noriega ,  Feifei Ng ,  Marie-Emérentienne Cagnon ,  Victor Nicoulin ,  Silvio Curia ,  Jean-Manuel Cros

IPC: A61K47/34 ,  A61K31/5415 ,  A61K31/18 ,  A61K9/00

CPC classification number: A61K47/34 ,  A61K9/0024 ,  A61K31/18 ,  A61K31/5415

Abstract: The present invention provides a pharmaceutical composition comprising:

a multi-branched copolymer comprising at least three polyester arms, wherein the polyester is poly(ε-caprolactone-co-lactic acid), attached to a central core which comprises a polyether, and wherein the multi-branched copolymer is substantially insoluble in aqueous solution, further comprising at least one pharmaceutically active ingredient, and a pharmaceutically acceptable organic solvent in an amount of at least 20% (w/w %) of the total composition.

公开(公告)号：US20230310321A1

公开(公告)日：2023-10-05

申请号：US18322693

申请日：2023-05-24

Applicant: Nano PharmaSolutions, Inc.

Inventor： Kay Olmstead ,  Saeyeon Lee ,  Seok-Keun Koh

IPC: A61K9/16 ,  A61K9/14 ,  A61K31/05 ,  A61K31/122 ,  A61K31/192 ,  A61K31/381 ,  A61K31/4422 ,  A61K31/5415 ,  A61K31/55

CPC classification number: A61K9/1676 ,  A61K9/14 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/1694 ,  A61K31/05 ,  A61K31/122 ,  A61K31/192 ,  A61K31/381 ,  A61K31/4422 ,  A61K31/5415 ,  A61K31/55

Abstract: Provided herein is a coated particle comprising: (i) a microparticle that comprises a pharmaceutically acceptable excipient and (ii) nanoparticles of a therapeutic agent, wherein the surface of the microparticle is coated with the nanoparticles. Also provided herein is a pharmaceutical composition comprising the coated particle. Furthermore, provided herein are methods of their preparation.

公开(公告)号：US20230285691A1

公开(公告)日：2023-09-14

申请号：US18144775

申请日：2023-05-08

Applicant: ALEXZA PHARMACEUTICALS, INC.

Inventor： Martin J. WENSLEY ,  Marc GLAZER ,  James BRESSON ,  Ryan TIMMONS ,  Daniel J. MYERS

IPC: A61M11/04 ,  A61M15/06 ,  A61K9/12 ,  A61K9/00 ,  A61M15/00 ,  A61M11/00 ,  A61K31/135 ,  A61K31/138 ,  A61K31/196 ,  A61K31/197 ,  A61K31/433 ,  A61K31/4468 ,  A61K31/451 ,  A61K31/4525 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5415 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61K31/7076

CPC classification number: A61M11/042 ,  A61K9/0009 ,  A61K9/007 ,  A61K9/12 ,  A61K31/135 ,  A61K31/138 ,  A61K31/196 ,  A61K31/197 ,  A61K31/433 ,  A61K31/4468 ,  A61K31/451 ,  A61K31/4525 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5415 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61K31/7076 ,  A61M11/001 ,  A61M11/041 ,  A61M15/00 ,  A61M15/0015 ,  A61M15/06 ,  A61M11/047 ,  A61M2205/3653 ,  A61M2205/8268

Abstract: Drug supply units are disclosed which comprise substrates having a plurality of holes formed therein.

公开(公告)号：US20230285329A1

公开(公告)日：2023-09-14

申请号：US18200557

申请日：2023-05-22

Applicant: Duke University ,  National University of Singapore

Inventor： Dwight D. Koeberl ,  Paul M. Yen ,  Benjamin L. Farah

IPC: A61K31/137 ,  A61K31/436 ,  A61K31/05 ,  A61K31/155 ,  A61K31/192 ,  A61K38/47 ,  A61K31/522 ,  A61K38/46 ,  A61K31/198 ,  A61K31/12 ,  A61K31/216 ,  A61K31/352 ,  A61K31/167 ,  A61P3/00 ,  A61K31/277 ,  A61K31/355 ,  A61K31/385 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/575 ,  A61K31/7016 ,  A61K33/00

CPC classification number: A61K31/137 ,  A61K31/436 ,  A61K31/05 ,  A61K31/155 ,  A61K31/192 ,  A61K38/47 ,  C12Y302/0102 ,  A61K31/522 ,  A61K38/465 ,  A61K31/198 ,  A61K31/12 ,  A61K31/216 ,  C12Y301/04012 ,  C12Y302/01049 ,  A61K31/352 ,  A61K31/167 ,  C12Y302/01022 ,  C12Y302/01045 ,  C12Y302/01076 ,  A61P3/00 ,  A61K31/277 ,  A61K31/355 ,  A61K31/385 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/575 ,  A61K31/7016 ,  A61K33/00

Abstract: The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.

公开(公告)号：US11752117B2

公开(公告)日：2023-09-12

申请号：US17728167

申请日：2022-04-25

Applicant: Nino Sorgente ,  Gabriele Thumann

Inventor： Nino Sorgente ,  Gabriele Thumann

IPC: A61K31/175 ,  A61K31/451 ,  A61K31/13 ,  A61P27/06 ,  A61K9/00 ,  A61K31/5415 ,  C12Q1/6811

CPC classification number: A61K31/175 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/13 ,  A61K31/451 ,  A61K31/5415 ,  A61P27/06 ,  C12Q1/6811

Abstract: Provided herein are methods of treating glaucoma in a patient, comprising: obtaining a biological sample from the patient; testing the biological sample for presence of a mutation in Kir6.2 protein or KCNJ11 gene and a mutation in the Aquaporin-9 protein or AQP-9 gene; and provided that the biological sample tests positive for the presence of a mutation in Kir6.2 protein or KCNJ11 gene and a mutation in the AQP-9 gene or aquaporin-9 protein, administering to the patient a therapeutically effective amount of a sulfonylurea such as tolbutamide or a physiologically equivalent salt or solvate thereof and a pharmaceutically acceptable carrier. Also provided herein are methods of maintaining and/or improving eye health in a subject, comprising: administering to the patient a therapeutically effective amount of tolbutamide or a physiologically equivalent salt or solvate thereof, and a pharmaceutically acceptable carrier.

公开(公告)号：US11738085B2

公开(公告)日：2023-08-29

申请号：US17809151

申请日：2022-06-27

Applicant: AXSOME THERAPEUTICS, INC.

Inventor： Herriot Tabuteau

IPC: A61K31/5415 ,  A61K31/4439 ,  A61K9/00 ,  A61P25/06 ,  A61K47/02 ,  A61K47/69 ,  A61K47/40 ,  A61K9/20 ,  C08B37/16 ,  A61K45/06

CPC classification number: A61K47/02 ,  A61K9/0053 ,  A61K9/2009 ,  A61K31/4439 ,  A61K31/5415 ,  A61K45/06 ,  A61K47/40 ,  A61K47/6951 ,  A61P25/06 ,  C08B37/0012 ,  C08B37/0015

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.